NYU Langone Health
The purpose of this research study is to see if offering genetic testing for cancer-related genes is feasible and acceptable for patients presenting for gynecology clinic visits, instead of needing to see specialized providers or needing to meet specific criteria. The primary aim to assess the proportion of patients who undergo genetic testing, and the proportion of patients with pathogenic variants.
Genetic Testing
Natera® Empower™ hereditary cancer panel test
Specialist Referral
NA
| Study Type : | INTERVENTIONAL |
| Estimated Enrollment : | 600 participants |
| Masking : | NONE |
| Primary Purpose : | SCREENING |
| Official Title : | Universal Genetic Testing for Cancer Risk Reduction |
| Actual Study Start Date : | 2025-03-04 |
| Estimated Primary Completion Date : | 2026-12-31 |
| Estimated Study Completion Date : | 2027-12-31 |
Information not available for Arms and Intervention/treatment
| Ages Eligible for Study: | 25 Years to 39 Years |
| Sexes Eligible for Study: | FEMALE |
| Accepts Healthy Volunteers: | 1 |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
RECRUITING
NYU Langone Health
New York, New York, United States, 10016